Pfizer announces that the second generation of EGFR-Tyrosine kinase inhibitors has landed in China

lung cancer ranks first in the morbidity and mortality of all types of cancer in China. NSCLC accounts for about 85% of all lung cancer cases. EGFR is the most common mutation type in NSCLC patients in China, with about 50% of patients with late-stage EGFR mutation.Recently, Pfizer announced that the second generation of EGFR-Tyrosine kinase inhibitor (TKI) targeted drug dacotinib (commodity name: Dozerrun ®) has officially landed in China, and launched the EAR Lung Cancer Precision Academy to bring new precision treatment options to lung cancer patients.On May 15 this year, dacotinib tablets were approved by China's State Drug Administration (NMPA) and can be used for first-line treatment in patients with partial late stage or metastasis non-small cell lung cancer (NSCLC) patients with exosome loss mutation No. 19 exosome 19 or exon L858R replacement mutation No. 21.In September 2018, the U.S. Food and Drug Administration (FDA) granted priority vetting eligibility for the first-line treatment of patients with localized late stage or metastasis EGFR mutations.Currently, Dakota has been approved for first-line treatment of advanced lung cancer in the United States, the European Union, Japan, Canada, etc., and has been approved by regulators in China for almost simultaneous submission of applications and regulatory approval. (Drug Information Network)